Treatment

Understanding QTc Warnings and VMAT2 Inhibitors

01/05/2017

Drs. Jain and Kumar explain QTc warnings as they relate to VMAT2 inhibitors for the treatment of tardive dyskinesia.

Popular Now

News

Study: Behavioral Health, Not COVID Symptoms, Fueled Early Surge in Telehealth Usage

01/12/2021

A RAND study published in the Journal of Medical Internet Research finds that telehealth usage soared during the early months of the COVID-19 pandemic, but it was behavioral health diagnoses largely driving the surge, not COVID-related...

A RAND study published in the...

01/12/2021

Behavioral Healthcare Executive

News

Meta-Analysis Supports Use of VMAT2 Inhibitors for Tardive Dyskinesia

06/02/2020

A meta-analysis and systematic review published in The Journal of Clinical Psychiatry supports the use of vesicular monoamine transporter 2 (VMAT2) inhibitors for the treatment of tardive dyskinesia (TD).

A meta-analysis and systematic...

06/02/2020

Psychiatry & Behavioral Health

Quiz

Quiz: Incidence and Prevalence of TD

04/19/2021

Psychiatry & Behavioral Health

News

Tardive Dyskinesia Improvement Sustained With Long-term Valbenazine

06/15/2021

Once-daily valbenazine was effective and generally well tolerated in adults with tardive dyskinesia who took the drug for up to 48 weeks, according to a study published online in The Journal of Clinical Psychiatry. “Results indicated...

Once-daily valbenazine was...

06/15/2021

Psychiatry & Behavioral Health

Videos

Advancing the Management of Insomnia: Diagnostic and Therapeutic Strategies for Success

07/01/2021

Psychiatry & Behavioral Health

Sign Up

Psychiatry & Behavioral Health Newsletter

Understanding QTc Warnings and VMAT2 Inhibitors

Popular Now

Sign Up

Specialties

Events

Year Round Education

HMP Global Products